Carna Biosciences, Inc. reported consolidated earnings results for the six months ended June 30, 2017. For the period, net sales were JPY 326 million against JPY 442 million a year ago. Operating loss was JPY 291 million against JPY 195 million a year ago. Ordinary loss was JPY 297 million against JPY 208 million a year ago. Loss attributable to owners of parent was JPY 316 million against JPY 33 million a year ago. Basic loss per share was JPY 34.03 against JPY 3.71 a year ago. Loss before income taxes was JPY 314,968,000 against JPY 32,607,000 a year ago.

For the full year ending December 31, 2017, the company expects to report, net sales of JPY 1,440 million, operating profit of JPY 39 million, ordinary profit of JPY 35 million, profit attributable to owners of parent of JPY 6 million or profit per share of JPY 0.71.